Do TP - Search Results

1

Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study.

Jantzen FT, Chaudhry BA, Younis S, Nørgaard I, Cullum CK, Do TP, Beier D, Amin FM. Jantzen FT, et al. Among authors: do tp. Sci Rep. 2024 Aug 5;14(1):18068. doi: 10.1038/s41598-024-68915-5. Sci Rep. 2024. PMID: 39103416 Free PMC article.

2

Therapeutic novelties in migraine: new drugs, new hope?

Do TP, Guo S, Ashina M. Do TP, et al. J Headache Pain. 2019 Apr 17;20(1):37. doi: 10.1186/s10194-019-0974-3. J Headache Pain. 2019. PMID: 30995909 Free PMC article. Review.

3

Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Pellesi L, et al. Among authors: do tp. Headache. 2020 Jun;60(6):1056-1065. doi: 10.1111/head.13843. Epub 2020 May 21. Headache. 2020. PMID: 32437038 Review.

4

The migraine landscape on YouTube: A review of YouTube as a source of information on migraine.

Saffi H, Do TP, Hansen JM, Dodick DW, Ashina M. Saffi H, et al. Among authors: do tp. Cephalalgia. 2020 Oct;40(12):1363-1369. doi: 10.1177/0333102420943891. Epub 2020 Jul 23. Cephalalgia. 2020. PMID: 32703016

5

Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunteers.

Ghanizada H, Iljazi A, Ashina H, Do TP, Al-Karagholi MA, Amin FM, Ashina M. Ghanizada H, et al. Among authors: do tp. Cephalalgia. 2021 Jan;41(1):99-111. doi: 10.1177/0333102420970489. Epub 2020 Nov 26. Cephalalgia. 2021. PMID: 33241720

6

Migraine: epidemiology and systems of care.

Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, Krymchantowski AV, Lebedeva ER, Ravishankar K, Yu S, Sacco S, Ashina S, Younis S, Steiner TJ, Lipton RB. Ashina M, et al. Among authors: do tp. Lancet. 2021 Apr 17;397(10283):1485-1495. doi: 10.1016/S0140-6736(20)32160-7. Epub 2021 Mar 25. Lancet. 2021. PMID: 33773613 Review.

7

Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants.

Do TP, Al-Saoudi A, Ashina M. Do TP, et al. Rev Neurol (Paris). 2021 Sep;177(7):827-833. doi: 10.1016/j.neurol.2021.06.005. Epub 2021 Jul 20. Rev Neurol (Paris). 2021. PMID: 34294458 Review.

8

Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment.

Dominguez-Moreno R, Do TP, Ashina M. Dominguez-Moreno R, et al. Among authors: do tp. Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):225-231. doi: 10.1097/MED.0000000000000717. Curr Opin Endocrinol Diabetes Obes. 2022. PMID: 35066541 Review.

9

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.

Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H, Amin FM. Cullum CK, et al. Among authors: do tp. J Headache Pain. 2022 Jun 2;23(1):61. doi: 10.1186/s10194-022-01433-9. J Headache Pain. 2022. PMID: 35655137 Free PMC article.

10

Use of Non-pharmacological Therapies in Individuals With Migraine Eligible for Treatment With Monoclonal Antibodies Targeting Calcitonin Gene-Related Peptide (CGRP)-Signaling: A Single-Center Cross-Sectional Observational Study.

Rundblad L, Cullum CK, Sacco S, Gil-Gouveia R, Uludüz D, Do TP, Amin FM. Rundblad L, et al. Among authors: do tp. Front Pain Res (Lausanne). 2022 Jul 13;3:935183. doi: 10.3389/fpain.2022.935183. eCollection 2022. Front Pain Res (Lausanne). 2022. PMID: 35910264 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters